2022
Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers
ZAVESKY, Ludek, Eva JANDÁKOVÁ, Vít WEINBERGER, Luboš MINÁŘ, Veronika HANZIKOVA et. al.Základní údaje
Originální název
Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers
Autoři
ZAVESKY, Ludek (203 Česká republika, garant), Eva JANDÁKOVÁ (203 Česká republika, domácí), Vít WEINBERGER (203 Česká republika, domácí), Luboš MINÁŘ (203 Česká republika, domácí), Veronika HANZIKOVA (203 Česká republika), Daniela DUSKOVA (203 Česká republika), Adela FARIDOVA (203 Česká republika), Radovan TURYNA (203 Česká republika), Ondrej SLANAR (203 Česká republika), Ales HORINEK (203 Česká republika) a Milada KOHOUTOVA (203 Česká republika)
Vydání
MOLECULAR BIOLOGY REPORTS, DORDRECHT, Springer, 2022, 0301-4851
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10608 Biochemistry and molecular biology
Stát vydavatele
Nizozemské království
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.800
Kód RIV
RIV/00216224:14110/22:00125182
Organizační jednotka
Lékařská fakulta
UT WoS
000739770300002
Klíčová slova anglicky
Biomarker; Breast cancer; microRNA; miR-451a; miR-548b-5p; U6 snRNA
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 20. 7. 2022 09:28, Mgr. Tereza Miškechová
Anotace
V originále
Background Breast cancer is a leading cause of cancer-related death in women. Most cases are invasive ductal carcinomas of no special type (NST breast carcinomas). Methods and Results In this prospective, multicentric biomarker discovery study, we analyzed the expression of small non-coding RNAs (mainly microRNAs) in plasma by qPCR and evaluated their association with NST breast cancer. Large-scale expression profiling and subsequent validations have been performed in patient and control groups and compared with clinicopathological data. Small nuclear U6 snRNA, miR-548b-5p and miR-451a have been identified as candidate biomarkers. U6 snRNA was remarkably overexpressed in all the validations, miR-548b-5p levels were generally elevated and miR-451a expression was mostly downregulated in breast cancer groups. Combined U6 snRNA/miR-548b-5p signature demonstrated the best diagnostic performance based on the ROC curve analysis with AUC of 0.813, sensitivity 73.1% and specificity 82.6%. There was a trend towards increased expression of both miR-548b-5p and U6 snRNA in more advanced stages. Further, increased miR-548b-5p levels have been partially associated with higher grades, multifocality, Ki-67 positivity, and luminal B rather than luminal A samples. On the other hand, an association has been observed between high miR-451a expression and progesterone receptor positivity, lower grade, unifocal samples, Ki-67-negativity, luminal A rather than luminal B samples as well as improved progression-free survival and overall survival. Conclusions Our results indicated that U6 snRNA and miR-548b-5p may have pro-oncogenic functions, while miR-451a may act as tumor suppressor in breast cancer.